Joellen Schilkdraut
Professor
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (29)
Background: Menstrual cycle characteristics—including age at menarche and cycle length— have been associated with ovarian cancer risk in White women. However, the associations between menstrual cycle characteristics and ovarian cancer risk among Black women have been sparsely studied. Methods: Using the Ovarian Cancer in Women of African Ancestry (OCWAA) Consortium that includes 1,024 Black and 2,910 White women diagnosed with epithelial ovarian cancer (EOC) and 2,325 Black and 7,549 White matched controls, we investigated associations between menstrual cycle characteristics (age at menarche, age at menstrual regularity, cycle length, and ever missing three periods) and EOC risk by race and menopausal status. Multivariable logistic regression was used to calculate odds ratios (OR) and 95% confidence intervals (CI). Results: Black women were more likely to be Conclusions: Earlier age at menarche and cycle irregularity are associated with increased EOC risk for White but not Black women. Impact: Associations between menstrual cycle characteristics and EOC risk were not uniform by race.
Year:
2025
Kaplan–Meier curves of OS in ( A ) main tumor groups ( n = 582)—MBOT, MOC, LGI, and UGI; ( B ) patients with MOC by FIGO stage ( n = 184); ( C ) patients with MOC by pattern of invasion in all stages ( n = 178); and ( D ) patients with stage I MOC ( n = 134), by pattern of invasion.
Year:
2025
Schema of study numbers for each analysis to describe different cohort numbers due to pathology review and missing data. MOC, mucinous ovarian carcinoma; MBOT, mucinous borderline ovarian tumor; LGI, lower gastrointestinal; UGI, upper gastrointestinal; SISH, silver in situ hybridization.
Year:
2025
Heat map of unsupervised clustering analysis. Contains all samples with a concordant pathology diagnosis ( n = 497), with MOC grouped by FIGO stage. Labels show main clusters and diagnoses. Gene-expression values are normalized and logarithm base 2 transformed. dx, diagnosis.
Year:
2025
Germline variants and somatic mutations in homologous recombination pathway genes prioritized in the 2020 American Society of Clinical Oncology (ASCO) recommendation for genetic testing in ovarian cancer
Year:
2025
Background: Half of ovarian high-grade serous carcinomas (HGSC) have homologous recombination deficiency (HRD). However, HRD is not well characterized in Black individuals who experience worse survival after a diagnosis of HGSC. The objective of this study was to characterize ovarian HGSC HRD and examine its association with survival by self-reported race. Methods: HRD features were identified using matched tumor–normal whole-exome and RNA sequencing in an HGSC cohort. We calculated age- and stage-adjusted HR and 95% confidence intervals (CI) for survival, comparing individuals with a feature to those without, separately by self-reported race. Results: Any HRD was associated with a 32% reduced risk of death in Black individuals compared with a 62% reduction in White individuals (Black HR = 0.68; 95% CI, 0.43–1.09; White HR = 0.38; 95% CI, 0.14–1.04). More of the germline and somatic variants detected among Black individuals were unannotated or variants of uncertain significance (VUS; germline 65% vs. 45%; somatic 62% vs. 50%). Black individuals with germline unannotated/VUS were more likely to have tumors with HRD scarring and a first-degree family history of breast or ovarian cancer compared with those without (HRD scar 71.4% vs. 49.6%; family history 68.4% vs. 34.6%). Conclusions: HRD testing informs precision-based medicine approaches that improve outcomes, but a higher proportion of VUS among Black individuals may complicate referral for such care leading to worse outcomes for Black individuals. Impact: Our findings emphasize the importance of recruiting diverse individuals in genomics research and better characterizing VUS.
Year:
2025
Background: Germline genetics may influence tumor molecular characteristics and ultimately cancer survival. Studies of tumor characteristics, including our epithelial ovarian cancer (EOC) studies of Black women in the United States, may have RNA sequencing (RNA-seq) data from archival tumor tissue but lack germline DNA for at least some individuals. Incomplete germline DNA measurements impede analyses of important measures such as global genetic ancestry, often used in downstream analyses, by reducing sample sizes. Methods: The study population consists of 184 women who participated in two population-based studies of EOC with both germline and formalin-fixed, paraffin-embedded (FFPE) tumor samples and an additional 58 women diagnosed with EOC from the same two studies with only FFPE tumor tissue. We used tumor RNA-seq data to calculate proportions of African, European, and Asian genetic ancestry using a pipeline built on the packages SeqKit, HISAT2, SAMtools, BCFtools, PLINK, and ADMIXTURE. Women from the 1000 Genomes Project were used as the reference populations, and germline genetic ancestry estimates from blood or saliva were used as the baseline comparison. We evaluated multiple quality control strategies to improve genetic ancestry estimation. Results: Correlations between tumor RNA-seq–derived estimates of genetic ancestry from our pipeline and germline-derived African and European genetic ancestry ranged between 0.76 and 0.94. Conclusions: RNA-seq data from archival FFPE tumor tissue can be confidently and efficiently used to approximate global genetic ancestry in an admixed population when germline DNA is unavailable. Impact: This approach supports analyses of genetic ancestry and cancer when germline samples are not available.
Year:
2025
Supplementary Table S2 shows the distribution of SNP type stratified by whether or not data from a participant's tumor sample met the proposed SNP threshold to improve genetic ancestry estimation and overall.
Year:
2025
Supplementary Figure S1 shows the difference in distributions of African genetic ancestry subpopulation proportions as calculated from germline DNA and tumor RNASeq (n = 184; ESN = Esan, GWD = Gambian, LWK = Luhya, MSL = Mende, YRI = Yoruba).
Year:
2025
Background: Germline alleles near genes encoding certain immune checkpoints (CTLA4, CD200) are associated with autoimmune/autoinflammatory disease and cancer, but in opposite ways. This motivates a systematic search for additional germline alleles with this pattern with the aim of identifying potential cancer immunotherapeutic targets using human genetics. Methods: Pairwise fixed effect cross-disorder meta-analyses combining genome-wide association studies (GWAS) for breast, prostate, ovarian and endometrial cancers (240,540 cases/317,000 controls) and seven autoimmune/autoinflammatory diseases (112,631 cases/895,386 controls) coupled with in silico follow-up. Results: Meta-analyses followed by linkage disequilibrium clumping identified 312 unique, independent lead variants with p 0.5) with at least one intra-tumor T/myeloid cell infiltration marker (CD4, CD8A, CD11B, CD45) in every one of the cancer types. Tumor single-cell RNA-Seq data from all cancer types showed that the five genes were more likely to be expressed in intra-tumor immune versus malignant cells. The five lead SNPs corresponding to these genes were linked to them via the expression of quantitative trait locus mechanisms and at least one additional line of functional evidence. Proteins encoded by the genes were predicted to be druggable. Conclusions: We provide population-scale germline genetic and functional genomic evidence to support further evaluation of the proteins encoded by IRF1, IKZF1, SPI1, SH2B3 and LAT as possible targets for cancer immunotherapy.
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Collaborators (82)
Charlie Gourley
University of Edinburgh
Patricia Moorman
Professor
Duke University
Sue K. Park
Professor
Seoul National University College of Medicine
Lynn Rosenberg
Boston University
Heather Wheeler
Professor
Loyola University Chicago
Hae Kyung Im
University of Chicago
Kathryn Terry
Co-Scientific Director
Boston Children's Hospital
Elizabeth Christie
Peter MacCallum Cancer Institute
Timothy Budden
Lecturer
University of Liverpool
Lucas A Salas
Assistant Professor
Dartmouth College Geisel School of Medicine
Beth Karlan
Vice Chair
University of California, Los Angeles
Chad Huff
Professor
The University of Texas MD Anderson Cancer Center
Anna Jakubowska
Head
Pomeranian Medical University
Lynne Wilkens
Professor
University of Hawaii at Manoa
Anthony Swerdlow
Professor of Epidemiology
Institute of Cancer Research Sutton
Heather M Ochs-Balcom
Professor & Associate Chair
University at Buffalo
Matthew Wakefield
University of Melbourne
Martin Widschwendter
Professor; Director
University of Innsbruck
P. M. Webb
Group Leader
QIMR Berghofer Medical Research Institute
Martin Köbel
Associate Professor
University of Calgary
Gregory Way
Associate Professor
University of Colorado Anschutz Medical Campus
Estrid V. Hoegdall
University of Copenhagen
Siddhartha P Kar
University Associate Professor
University of Cambridge
Paul Timpson
Co-Director ACRF (INCITe) Centre
Garvan Institute of Medical Research
James D Brenton
University of Cambridge
Jae-Weon Kim
Professor
Seoul National University Hospital
Cezary Cybulski
Pomeranian Medical University
Lyndal Anderson
University of Western Sydney
Claus Høgdall
Professor in Clinical Gynecologic Oncology
University of Copenhagen
Lindsay J Collin
Assistant Professor
Emory University
Anthony Gill
University of Sydney
Linda Cook
Professor
University of Colorado Cancer Center
Paul James
Head of Adult Genetics
The Royal Melbourne Hospital Royal Park Campus
Parham Minoo
Associate Clinical Professor of Pathology
University of Calgary
Angela Brooks-Wilson
Simon Fraser University
Tomasz Kluz
Professor
Rzeszów University
Michael Anglesio
Associate Professor
The University of British Columbia
Ramona Erber
W2-Professorin, Oberärztin
University of Regensburg
Nicholas Hawkins
Emeritus Professor
UNSW Sydney
Usha Menon
Professor of Gynaecological Oncology
University College London
Kristin Guertin
Assistant Professor
University of Connecticut
Evan Myers
Duke University
Michael P Epstein
Emory University School of Medicine
Sandra Orsulic
Professor
University of California, Los Angeles
Cheng-Han Lee
Associate Professor
University of Alberta
Casey Greene
Director
University of Colorado Anschutz Medical Campus
Ian Campbell
Group Leader
Peter MacCallum Cancer Institute
Stacey J. Winham
Mayo Clinic College of Medicine and Science
Jae-Hoon Kim
Yonsei University College of Medicine
Anna H. Wu
Professor
University of Southern California
C Blake Gilks
-
Peter Fasching
-
Francesmary Modugno
University of Pittsburgh
Alexander Hein
-
Kylie-Ann Mallitt
Senior Lecturer in Biostatistics
University of Sydney
Dale Garsed
University of Melbourne
Philip Crowe
Professor Surgery
University of New South Wales
Renée Fortner
Head of Division
Deutsches Krebsforschungszentrum
K Sundfeldt
Professor/Consultant
University of Gothenburg, Sahlgrenska Academy
Tomasz Huzarski
Pomeranian Medical University
Byoung-Gie Kim
Sungkyunkwan University School of Medicine
Dane Cheasley
Senior Research Fellow
University in Western Australia
Gregg Nelson
Gynecologic Oncologist
University of Calgary
Jennifer Anne Doherty
Professor
University of Utah
Paul Pharoah
Professor of Cancer Epidemiology
Cedars-Sinai Medical Center
Brenda Y Hernandez
University of Hawaii
Natalie Davidson
Assistant Professor
University of Colorado Anschutz Medical Campus
Michael Edwin Jones
Senior Staff Scientist
Institute of Cancer Research
Kylie L Gorringe
Group Leader
Peter MacCallum Cancer Institute
Jan Lubiński
Head of Dept
Pomeranian Medical University
Veronica Setiawan
Associate Professor
University of Southern California
Mona El-Bahrawy
Imperial College London
Aleksandra Gentry-Maharaj
University College London
David G. Huntsman
The University of British Columbia
Janusz Menkiszak
Head of the University Clinic
Pomeranian Medical University
Clare Scott
Walter and Eliza Hall Institute of Medical Research
Elisa Bandera
Chief
Rutgers Cancer Institute of New Jersey
Susan Ramus
Professor of Molecular Oncology
University of New South Wales
Paul Cohen
University of Western Australia
Aline Talhouk
Assistant Professor
The University of British Columbia
Charlotte Joslin
University of Illinois Chicago (UIC)
David Lawson Morris
Professor of Surgery
University of New South Wales
Make your next move.
Prepare your application
Review drafts before you send them.